Den Europæiske Union - dansk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - splittet influenzavirus, inaktiveret, indeholdende antigen: a / vietnam / 1194/2004 (h5n1) som brugt belastning (nibrg-14) - influenza, human; immunization; disease outbreaks - vacciner - aktiv immunisering mod h5n1-subtype af influenza a-virus. denne angivelse er baseret på immunogenicitet data fra raske forsøgspersoner i alderen fra 18 år og op efter administration af to doser vaccine, der er fremstillet af en/vietnam/1194/2004 nibrg-14 (h5n1) (se afsnit 5. prepandemic influenza vaccine (h5n1) (split virion, inaktiveret, adjuvanted) glaxosmithkline biologicals 3. 75 µg bør anvendes i overensstemmelse med officielle retningslinjer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacciner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacciner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombinant vesikulær stomatitis virus (stamme, indiana) med en sletning af konvolutten glycoprotein, som er erstattet med zaire ebolavirus (stamme kikwit 1995) overflade glycoprotein - hæmoragisk feber, ebola - vacciner - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. brug af ervebo bør være i overensstemmelse med de officielle anbefalinger.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatitis b overflade antigen - hepatitis b - vacciner - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - respiratoriske syncytiale virusinfektioner - vacciner - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. se afsnit 4. 2 og 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - pandemic influenza vaccine (h5n1) (split virion, inaktiveret, adjuvanted) - influenza, human; immunization; disease outbreaks - vacciner - prophylax af influenza i en officielt erklæret pandemisk situation. pandemic influenza vaccine bør anvendes i overensstemmelse med officielle retningslinjer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vacciner - profylakse af influenza forårsaget af a (h1n1) v 2009 virus. celvapan bør anvendes i overensstemmelse med officielle retningslinjer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokok - vacciner - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mcm vaccine b.v. - difteri toxoid, tetanus toxoid, bordetella pertussis antigener: kighoste toxoid, trådformede hæmagglutinin, pertactin, fimbriae typer 2 og 3, hepatitis b surface antigen, der er produceret i gær celler, poliovirus (inaktiveret): type 1 (mahoney), type 2 (mef-1), type 3 (saukett), produceret i vero celler/ haemophilus influenzae type b polysakkarid (polyribosylribitol fosfat), der er konjugeret til meningokok-protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vacciner - vaxelis (dtap-hb-ipv-hib) er indiceret til primære og booster vaccination hos spædbørn og småbørn i alderen fra 6 uger, mod difteri, stivkrampe, kighoste, hepatitis b, polio og invasive sygdomme forårsaget af haemophilus influenzae type b (hib). brug af vaxelis bør være i overensstemmelse med officielle anbefalinger.